TORONTO, March 24, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the
“Company”) an emerging medical device company focused on prostate care, today announced that Steven Plymale has resigned his
position as the Company’s President and Chief Operating Officer to pursue other opportunities.
"It has truly been an honor and privilege to have worked alongside the talented team at Profound for the past six years,"
commented Mr. Plymale. "While the decision to leave the Company was a difficult one for me, I believe that it is very
well-positioned to continue its strong growth trajectory in 2017 and beyond.”
“Steve’s contributions to the development of both the Company and our TULSA-PRO® system have been immeasurable,” commented
Profound’s CEO, Arun Menawat. “On a personal note, he has been a friend and colleague for many years, and I sincerely wish
him the highest level of success in the future.”
Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The
Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which is designed to further demonstrate
the safety and effectiveness of this innovative technology. If successful, TACT is expected to support Profound's application
to the U.S. Food and Drug Administration for approval to market TULSA-PRO in the United States.
About Profound Medical Corp.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions
of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment
options often mean having to make difficult choices based on potential side effects that can significantly impact quality of
life. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate
cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where
patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO, which combines real-time Magnetic
Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is
designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential
side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited
to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always,
forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or
state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such
statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances
discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic
factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to
identify important factors that could cause actual actions, events or results to differ materially from those described in
forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as
required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts For further information, please contact: Stephen Kilmer Investor Relations skilmer@profoundmedical.com T: 647.872.4849 Or Rashed Dewan Vice President, Finance T: 647-476-1350
